Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in MayInitial Results From First Two ...

Reports as of December 31, Corvus had cash, cash equivalents and marketable securities of $52.M as compared to $27.1M as of December 31, 2023.

On a per-share basis, the Burlingame, California-based company said it had a loss of 18 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by ...